by Andrea Canton | May 27, 2020 | Odyssey
New videos have been developed by Picturing Health, to inform and promote behaviour that can reduce the spread of Coronavirus in Africa and South Asia. Through knowledge and information Picturing Health is aiding communities to slow the epidemic and protect those most...
by Andrea Canton | May 21, 2020 | Odyssey
The COVID-19 pandemic is affecting people and health services around the world. Many of the healthcare professionals involved with the ODYSSEY trial have been providing care to patients with COVID-19 in hospitals, clinics and communities and dealing with the public...
by odysseyadmin | Feb 11, 2020 | Odyssey
Results from the ODYSSEY trial will be presented at this year’s Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, USA. The trial team’s abstract titled “Adequate dolutegravir exposure dosed bid with rifampicin in children 6 to <18 years” has...
by Andrea Canton | Dec 20, 2019 | Odyssey
Using data from the ongoing P1093 and the ODYSSEY (PENTA20) study, ViiV Healthcare has filed submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV. If approved, this new formulation of dolutegravir...
by Andrea Canton | Oct 23, 2019 | Odyssey
Recruitment to the main trial is complete! The ODYSSEY study has reached a major milestone by completing the recruitment of participants to the main trial. Recruitment of children ≥14kg is complete with a total of 707 participants randomised altogether: 311 recruited...
by Andrea Canton | Aug 26, 2019 | Odyssey
ODYSSEY presented at ‘Annual Conference of the International Society for Clinical Biostatistics’ in Leuven, Belgium We are pleased to report that a presentation from the ODYSSEY team at MRC CTU at UCL was well received at the 40th Annual Conference of the...
Recent Comments